In a May 13, 2025 post on X, Chamath Palihapitiya, renowned Silicon Valley venture capitalist, entrepreneur, and former Facebook executive, provided the latest updates on Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) and its next-generation surgical imaging solution, designed to reduce repeat breast cancer surgeries.
At the time of publication of this BT Brief, Mr. Palihapitiya’s post has already garnered over 296,000 views.
Currently, Perimeter is commercializing its first FDA-cleared intraoperative imaging technology, the S-Series OCT, which provides surgeons with image resolutions capable of visualizing tissue structures at the cellular level down to the critical 2mm depth when assessing margins real-time in the OR.
In March 2025, Perimeter announced the submission of a Premarket Approval (PMA) application to the FDA for use of its next-generation, AI-enabled Perimeter B-Series during breast cancer surgeries in the U.S. The FDA PMA submission represented the achievement of a major milestone – Perimeter’s first pre-market regulatory submission for its AI-enabled, wide-field OCT technology, as well as for a specific indication label. The FDA PMA application, supported by recent pivotal trial results, is currently under review by the agency.
